Literature DB >> 22180736

Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.

Chikako Ogawa1, Yuen-Joyce Liu, Koichi S Kobayashi.   

Abstract

Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. It was first identified in bacterial cell wall peptidoglycan as an active component in Freund's complete adjuvant. In the cell, MDP is detected by NOD2, a cytoplasmic receptor belonging to the human innate immune system. NOD2 mutations are frequently observed in patients with Crohn's disease, an autoimmune disorder, suggesting the significance of the MDP-NOD2 pathway in activating immunity. For this reason, structural modifications of MDP and its derivatives have been extensively studied in an attempt to increase adjuvant activity and boost the immune response effectively for clinical use in the treatment of cancer and other diseases. This review summarizes the synthetic chemistry of MDP and its derivatives and discusses their pharmacological action and stereoselective synthesis.

Entities:  

Year:  2011        PMID: 22180736      PMCID: PMC3241611          DOI: 10.2174/157340711796817913

Source DB:  PubMed          Journal:  Curr Bioact Compd        ISSN: 1573-4072


  102 in total

1.  Synthesis and proinflammatory effects of peptidoglycan-derived neoglycopeptide polymers.

Authors:  A Siriwardena; M R Jørgensen; M A Wolfert; M L Vandenplas; J N Moore; G J Boons
Journal:  J Am Chem Soc       Date:  2001-08-22       Impact factor: 15.419

2.  IRAK-M is a negative regulator of Toll-like receptor signaling.

Authors:  Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

3.  Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Yoshio Wakatsuki; Ivan J Fuss; Warren Strober
Journal:  Immunity       Date:  2006-08-31       Impact factor: 31.745

4.  Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.

Authors:  Koichi S Kobayashi; Mathias Chamaillard; Yasunori Ogura; Octavian Henegariu; Naohiro Inohara; Gabriel Nuñez; Richard A Flavell
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

5.  Reduced Paneth cell alpha-defensins in ileal Crohn's disease.

Authors:  Jan Wehkamp; Nita H Salzman; Edith Porter; Sabine Nuding; Michael Weichenthal; Robert E Petras; Bo Shen; Elke Schaeffeler; Matthias Schwab; Rose Linzmeier; Ryan W Feathers; Hiutung Chu; Heriberto Lima; Klaus Fellermann; Tomas Ganz; Eduard F Stange; Charles L Bevins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

6.  Differential mRNA responses in human macrophages activated by interferon-gamma and muramyl dipeptide.

Authors:  M W Vermeulen; J R David; H G Remold
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

7.  Genetic variation and activity of mouse Nod2, a susceptibility gene for Crohn's disease.

Authors:  Yasunori Ogura; Lisa Saab; Felicia F Chen; Adalberto Benito; Naohiro Inohara; Gabriel Nuñez
Journal:  Genomics       Date:  2003-04       Impact factor: 5.736

8.  N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.

Authors:  D Kikelj; S Pecar; V Kotnik; A Stalc; B Wraber-Herzog; S Simcic; A Ihan; L Klamfer; L Povsic; R Grahek; E Suhadolc; M Hocevar; H Hönig; R Rogi-Kohlenprath
Journal:  J Med Chem       Date:  1998-02-12       Impact factor: 7.446

9.  Modulation of tumour necrosis factor production with desmuramyldipeptide analogues.

Authors:  S Simcic; B Wraber; M Sollner; U Urleb; S Gobec
Journal:  Pflugers Arch       Date:  2000       Impact factor: 3.657

10.  Role of nod2 in the response of macrophages to toll-like receptor agonists.

Authors:  Anne-Laure Pauleau; Peter J Murray
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

View more
  27 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

Review 2.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

3.  Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants.

Authors:  M Salem; J B Seidelin; S Eickhardt; M Alhede; G Rogler; O H Nielsen
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

4.  Synthesis and Application of Methyl N,O-Hydroxylamine Muramyl Peptides.

Authors:  Klare M Lazor; Junhui Zhou; Kristen E DeMeester; Elizabeth A D'Ambrosio; Catherine L Grimes
Journal:  Chembiochem       Date:  2019-03-21       Impact factor: 3.164

5.  Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition.

Authors:  Bram Priem; Mandy M T van Leent; Abraham J P Teunissen; Alexandros Marios Sofias; Vera P Mourits; Lisa Willemsen; Emma D Klein; Roderick S Oosterwijk; Anu E Meerwaldt; Jazz Munitz; Geoffrey Prévot; Anna Vera Verschuur; Sheqouia A Nauta; Esther M van Leeuwen; Elizabeth L Fisher; Karen A M de Jong; Yiming Zhao; Yohana C Toner; Georgios Soultanidis; Claudia Calcagno; Paul H H Bomans; Heiner Friedrich; Nico Sommerdijk; Thomas Reiner; Raphaël Duivenvoorden; Eva Zupančič; Julie S Di Martino; Ewelina Kluza; Mohammad Rashidian; Hidde L Ploegh; Rick M Dijkhuizen; Sjoerd Hak; Carlos Pérez-Medina; Jose Javier Bravo-Cordero; Menno P J de Winther; Leo A B Joosten; Andrea van Elsas; Zahi A Fayad; Alexander Rialdi; Denis Torre; Ernesto Guccione; Jordi Ochando; Mihai G Netea; Arjan W Griffioen; Willem J M Mulder
Journal:  Cell       Date:  2020-10-29       Impact factor: 41.582

6.  Anti-neoplastic and immunomodulatory potency of co-treatment based on bovine lactoferrin and/or muramyl dipeptide in tumor-bearing mice.

Authors:  Hany M Ibrahim; Azza H Mohamed; Mohamed L Salem; Gamalat Y Osman; Dalia S Morsi
Journal:  Toxicol Res (Camb)       Date:  2020-04-24       Impact factor: 3.524

7.  Exploring the chemical space of peptides for drug discovery: a focus on linear and cyclic penta-peptides.

Authors:  Bárbara I Díaz-Eufracio; Oscar Palomino-Hernández; Richard A Houghten; José L Medina-Franco
Journal:  Mol Divers       Date:  2018-02-14       Impact factor: 2.943

Review 8.  Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond.

Authors:  Mohammad Salem; Jakob Benedict Seidelin; Gerhard Rogler; Ole Haagen Nielsen
Journal:  Cell Mol Life Sci       Date:  2012-12-29       Impact factor: 9.261

9.  Proteasomal degradation of Nod2 protein mediates tolerance to bacterial cell wall components.

Authors:  Kyoung-Hee Lee; Amlan Biswas; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

10.  Interferon gamma boosts the nucleotide oligomerization domain 2-mediated signaling pathway in human dendritic cells in an X-linked inhibitor of apoptosis protein and mammalian target of rapamycin-dependent manner.

Authors:  Tünde Fekete; Gabor Koncz; Brigitta Szabo; Andrea Gregus; Eva Rajnavölgyi
Journal:  Cell Mol Immunol       Date:  2015-11-02       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.